Aspirin Desensitization/Challenge in Patients with Cardiovascular Diseases: Current Trends and Advances
- Authors: Aysa Rezabakhsh1, Hassan Soleimanpour2
-
View Affiliations Hide Affiliations1 Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 2 Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran
- Source: Frontiers in Clinical Drug Research - Anti Allergy Agents: Volume 5 , pp 147-189
- Publication Date: April 2022
- Language: English
Aspirin Desensitization/Challenge in Patients with Cardiovascular Diseases: Current Trends and Advances, Page 1 of 1
< Previous page | Next page > /docserver/preview/fulltext/9789815040616/chap5-1.gif
Aspirin, known as acetylsalicylic acid (ASA), is one of the most commonly used medications. Available as over-the-counter medicine, ASA is prescribed as a nonsteroidal anti-inflammatory and anti-platelet drug and has the potential to decrease pain and fever. ASA is also considered as a first-line drug for the treatment of some cardiovascular diseases such as coronary artery diseases (CAD) and myocardial infarction (MI). Subsequently, it has been demonstrated to reduce the morbidity and mortality rate of these diseases. Besides the beneficial effects, ASA has the potential to provoke some allergic reactions, particularly in patients with CAD. According to previous reports, in 1.5-2.6% of the subjects with CVD treated with ASA, aspirinexacerbated respiratory disease or chronic idiopathic urticaria were observed. In this book chapter, we aimed to summarize all-new achievements and novel findings of recent clinical advances related to the desensitization approaches following aspirin consumption in patients with CADs
-
From This Site
/content/books/9789815040616.chap5dcterms_subject,pub_keyword-contentType:Journal -contentType:Figure -contentType:Table -contentType:SupplementaryData105
